Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
600329
Helyezés a részvények között
#4374
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its... Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Republic of China. Its business activities are structured into two distinct divisions: Chinese Medicine and Western Medicine. The company's operations extend beyond its core offerings to include the production and distribution of Chinese, Western, and biological pharmaceutical items. It also engages in the wholesale and retail trade of medicines, biochemical pharmaceutical products, and everyday consumer goods, in addition to managing hospitals. Furthermore, Tianjin Pharmaceutical Da Ren Tang provides a comprehensive suite of services such as logistics, inventory management, equipment installation, and drug processing. It also offers pharmaceutical inspection, testing, and advisory services. In terms of its commercial model, the company supplies its proprietary branded medicinal products directly to wholesalers. Conversely, it acquires pharmaceuticals marketed under other brands from distributors, subsequently reselling these to other wholesale clients. Established in 1992 and based in Tianjin, People's Republic of China, the company was previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited before adopting its current name in May 2022.
Részvényárfolyam
$6.17
Piaci kapitalizáció
$3.52B
Változás (1 nap)
-0.05%
Változás (1 év)
-1.86%
Ország
CN
Kereskedés Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329)
Kategória
Healthcare
Bevétel a(z) Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329) részvényhez
Bevétel ekkor: Oct 2026 TTM: 0
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi árbevétele (TTM) 0. 2026 évben a vállalat 0 árbevételt ért el, amely megegyezik a 2026 évben elért 0 árbevételhez képest. Az árbevétel az a teljes összeg, amit a vállalat termékek vagy szolgáltatások eladásából generál. A nyereséggel ellentétben ebből nem vonódnak le költségek.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited bevételtörténete 2001 és 2026 között
Bevétel az év végén
| Év | Bevétel | Változtassa meg |
|---|---|---|
| 2025 | $702.84M | -29.79% |
| 2024 | $1.00B | -13.82% |
| 2023 | $1.16B | -2.87% |
| 2022 | $1.20B | 10.04% |
| 2021 | $1.09B | 7.51% |
| 2020 | $1.01B | 0.64% |
| 2019 | $1.00B | 8.65% |
| 2018 | $924.41M | 5.71% |
| 2017 | $874.43M | -2.75% |
| 2016 | $899.13M | -17.54% |
| 2015 | $1.09B | -4.70% |
| 2014 | $1.14B | 15.48% |
| 2013 | $990.83M | 20.44% |
| 2012 | $822.65M | 18.08% |
| 2011 | $696.67M | 32.38% |
| 2010 | $526.25M | 24.71% |
| 2009 | $421.97M | 21.73% |
| 2008 | $346.64M | 12.07% |
| 2007 | $309.30M | 11.54% |
| 2006 | $277.30M | -10.61% |
| 2005 | $310.21M | 21.98% |
| 2004 | $254.31M | 1.95% |
| 2003 | $249.43M | 12.25% |
| 2002 | $222.22M | 20.82% |
| 2001 | $183.92M | 0.00% |
Hasonló cégek vagy versenytársak bevétele
| Vállalat | Bevétel | Bevételkülönbség | Ország |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
